Sparse Batch Number Reporting for Biologicals in FDA's Adverse Event Reporting System (AERS)

被引：0
|
作者：
Vermeer, N. S. [1 ,2 ]
Straus, S. M. [2 ,3 ]
Teeuwisse, A. K. Mantel [1 ]
Egberts, T. C. [1 ]
Leufkens, H. G. [1 ,2 ]
De Bruin, M. L. [1 ,2 ]
机构：
[1] Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, UIPS, Utrecht, Netherlands
[2] Med Evaluat Board, The Hague, Netherlands
[3] Erasmus MC, Dept Med Informat, Rotterdam, Netherlands
来源：
DRUG SAFETY | 2011年 / 34卷 / 10期
关键词：
BIOPHARMACEUTICALS;
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
下载
收藏
页码：1002 / 1002
页数：1
相关论文
共 50 条
  • [1] REPORTING FREQUENCY OF QT-INTERVAL ABNORMALITIES IN THE FDA ADVERSE EVENT REPORTING SYSTEM (FDA_AERS)
    Raschi, E.
    Poluzzi, E.
    Koci, A.
    De Ponti, F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 84 - 84
  • [2] Increased Reporting to the FDA Adverse Event Reporting System (AERS) After Metoclopramidc Black Box Warning
    Sifuentes, Humberto
    Parakkal, Deepak
    Somarriba, Gabriela C.
    Leikin, Jerrold B.
    Ehrenpreis, Eli I.
    GASTROENTEROLOGY, 2011, 140 (05) : S726 - S726
  • [3] Accuracy of Reporting and Method for Classifying Progressive Multifocal Leukoencephalopathy (PML) within the FDA Adverse Event Reporting System (AERS)
    Kapasi, Anokhi J.
    Nguyen-Khoa, Bao-Anh
    Goehring, Earl L., Jr.
    Alexander, Kimberly
    Napalkov, Pavel K.
    Foskett, Nadia
    Jones, Judith K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S46 - S46
  • [4] Fatal reports in intramuscular vs oral antipsychotics in the FDA adverse event reporting system (AERS)
    Sorsaburu, Sebastian
    Chilcott, Karen E.
    DeLisle, F. Patrick
    Hornbuckle, Kenneth
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S222 - S222
  • [5] An evaluation of the FDA adverse event reporting system and the potential for reporting bias
    Monnot, Andrew D.
    Fung, Ernest S.
    Compoginis, Goli S.
    Towle, Kevin M.
    JOURNAL OF COSMETIC DERMATOLOGY, 2021, 20 (06) : 1849 - 1854
  • [6] Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS
    Kaori Kadoyama
    Akiko Kuwahara
    Motohiro Yamamori
    JB Brown
    Toshiyuki Sakaeda
    Yasushi Okuno
    Journal of Experimental & Clinical Cancer Research, 30
  • [7] Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS
    Kadoyama, Kaori
    Kuwahara, Akiko
    Yamamori, Motohiro
    Brown, J. B.
    Sakaeda, Toshiyuki
    Okuno, Yasushi
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2011, 30
  • [8] Disproportionate Lawyer Reporting of Inflammatory Bowel Disease Cases with Isotretinoin: A Review of the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS)
    Stobaugh, Derrick
    Deepak, Parakkal
    Sherid, Muhammed
    Ehrenpreis, Eli
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S638 - S639
  • [9] Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
    Sakaeda, Toshiyuki
    Kadoyama, Kaori
    Okuno, Yasushi
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2011, 8 (06): : 487 - 491
  • [10] PROTECTION VERSUS RISK OF PSORIASIS WITH USE OF CROHN'S DISEASE BIOLOGIC AGENTS: AN ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (AERS).
    Kip, K.
    Swoger, J.
    Grandinetti, L.
    Swoger, J.
    Barrie, A., III
    Greer, J.
    Regueiro, M.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2012, 175 : S143 - S143
12345